1 / 31

Fungus: SICU

Fungus: SICU. Bradley J. Phillips, M.D. Burn-Trauma-ICU Adults & Pediatrics. Fungal Infections-History. Opportunistic fungal infections rare before the 1960’s Virulent : Histoplasma, Coccidioides, Blastomyces Opportunistic : Candida, Cryptococcus, Aspergillus

fahim
Télécharger la présentation

Fungus: SICU

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fungus: SICU Bradley J. Phillips, M.D. Burn-Trauma-ICU Adults & Pediatrics

  2. Fungal Infections-History • Opportunistic fungal infections rare before the 1960’s • Virulent : Histoplasma, Coccidioides, Blastomyces • Opportunistic : Candida, Cryptococcus, Aspergillus • 1968- Kraus demonstrated invasive potential of fungus • 1980’s- potential for affecting outcome of the critically ill

  3. Fungal Infections-History • Candida: increased in rank from 8th to 4th most common nosocomial pathogen isolated in blood • Accounts for 8-15% of all hospital acquired positive blood cultures • Increased LOS: as much as 30 days • Increased mortality: 30-80%

  4. Candida • Most commonly isolated fungus • yeast form: colonization • mycelial form : invasive Blastospores Pseudohyphae

  5. Candida • BU surveillance in SICU • time period: 3 months (Jan-March/2001) • 251 patients total • 17 isolates • 13 Candida albicans (76. 5%) • 3 Candida glabrata (17.6%) • 1 Candida tropicalis (5.9 %)

  6. Candida albicans

  7. Candida glabrata

  8. Candida Tropicalis

  9. Colonization vs. Infection • Colonization: presence of organism without evidence of invasive infection • skin, urine, airway • Invasive infection: histologic presence of the pathogen in normally sterile tissues • biopsy specimens, foreign bodies • Dissemination: • positive blood cultures

  10. Diagnosis • Combination of: • Laboratory findings • Clinical findings • High index of suspicion Recognizing the risk factors for fungal infections !!!

  11. Risk for Fungus • Case -control study of 88 pairs of patients over 3 years • Risk factors: • Antibiotic use (0-2 vs 3-5) OR=12.50 • Hickman catheter OR=7.23 • Dialysis OR 18.13 • Candida :site other than blood OR=10.37 Wey et al. Archives of Internal Medicine, 1989

  12. Risk for Fungus • Severity of illness : APACHE II >10 • Ventilator use > 48 hours • broad spectrum antibiotics • indwelling access catheters • malnutrition • immunosuppression • burns Dean et al. The American Journal of Surgery, 1996 (review article)

  13. Fungus Among Trauma Patients • Retrospective case-control study • 459 trauma patients reviewed over 3 years • > 4 days in ICU, age > 16 • Risk factors studied • steroids • dialysis • burns • GI perforation • glucose > 180mg/dl • colonization • APACHE II • PRBC transfused • TPN • central line • vent Borzotta et al. Archives of Surgery, 1999

  14. Results • Infection rate of 4.4 % (20/459) • 33% colonization- did not relate to infection • No difference in mortality with/without infection • Only TPN was an independent risk factor • Univariate analysis showed significance (P<0.05) in the following: • number of units transfused in the first 24hrs • GI perforation • hemodialysis • TPN

  15. What Does This Mean?What Is the Practical Value?How Do We Manage Our Patients? ?

  16. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candida Infections Harbor-UCLA Research and Educational Institute St. John’s Cardiovascular Research Center Clinical Infectious Disease 1997

  17. Question 1 • Should all candidemic patients be treated with an antifungal? • High mortality rates 30-80% • Current methods of risk factor analysis not accurate enough to assign deep-tissue infection • 19/20 investigators -affirmative answer • inaccuracy in determining which patients need treatment • therapeutic options with less toxic effects are available • morbidity/long term sequele in untreated patients is high

  18. Question 2 • What antifungal agents should be used in the management of candidemia? • Study of nonneutropenic patients with candidemia treated with either Ampho B or Fluconazole for 2 weeks after the last positive cultures showed no difference. • Stable with no evidence of seeding: 20/20 chose Fluconazole • Previous treatment with Fluconazole: 17/20 chose Ampho B

  19. Question 3 • When should empiric therapy given to nonneutropenic patients? • Consider for critically ill with signs of infection who have not responded to optimal antibiotic therapy with evaluation for bacterial infection • 18/20 investigators treated with > 2 risk factors and Candida • in sputum or urine • 10/20 investigators treated with no Candida isolated

  20. BU-SICU Fungal Protocol • Blood • fundoscopic exam • repeat cultures • treat with Fluconazole load 800mg, then 400mg/day for 7-14 days • C. Albicans, C. tropicalis, C. parapsilosis, C. lusitania • treat with Amphotericin B 0.5-1.0 mg/kg/day • Peritoneal fluid • Fluconazole 800 mg/d load, then 400mg/day for 7-14 days

  21. BMC-SICU Fungal Protocol

  22. BMC-SICU Fungal Protocol • Fungal infection must be considered when the patient fails to improve despite appropriate or broad spectrum antibiotic therapy. Empiric treatment should be started in those patients with two or more of the following risk factors: • 1. > 1 week of antibiotic therapy • 2. Immunosuppression • 3. Long term intravenous catheters • 4. Violation of the GI tract • 5. Intra-abdominal abscesses • 6. Prolonged hospital stay • 7. SIRS or Multi-systemOrgan Failure

  23. BMC-SICU Fungal Protocol • 1. Send fungal cultures of urine, sputum, blood, other body fluids or foreign bodies and perform a fundoscpic exam • 2. Treat with Fluconazole 800mg IV/day as loading dose, then 400mg IV/day for 7-14 days. For renal failure patients: CrCl > 50ml/min 400mg/day 20-50 ml/min 200 mg/day 10-20 ml/min 100 mg/day dialysis pts 400mg after dialysis

  24. Fluconazole (Diflucan®) • Aims at ergosterol of cell membranes • Availabe forms: tablets, suspension, IV • Excretion: 80% in urine as active form, • Half life: 30 hours • Adverse effects: nausea, HA, rash • hepatic reactions, SJ syndrome • Drug interactions: coumadin, CSA, dilantin, oral hypoglycemics, rifampin, seldane

  25. Case • 24y/o AA male with single GSW to left mid axillary line at the level of the 10th rib. • Awake and alert on presentation • Taken immediately to the OR for exploration

  26. Case • Left chest tube placed in the OR • Midline exploration performed Fajitas! Fajitas! More fajitas!!!

  27. Case • Left nephrectomy for a shattered kidney • Repair of anterior and posterior gastrotomy • Repair of duodenal injury with pyloric exclusion (Jordan procedure) • Feeding jejunostomy tube placement

  28. Case • Pt with persistent fevers and elevated white count despite triple antibiotics. • Fever work-up performed • Candida albicans grew from sputum, blood and peritoneal cavity

  29. Case • Risk factors: • GI perforation • multiple antibiotics • indwelling catheters • immunosuppression

  30. Case • Currently on the floor, decannulated trach site, tolerating PO intake. • Barium study shows open pylorus, functioning gastrojejunostomy and no evidence of leak or stricture at duodenum.

  31. Question 4 • What is the role of prophylactic antifungal agents in nonneutropenic patients? Fungal therpay should not be given on a routine basis If given, Fluconazole is the drug of choice.

More Related